According to a report by Russian business newspaper on September 12, British American Tobacco (BAT) has started selling vape product Vuse in Russia after selling its operations in Russia and Belarus to a management team from Russia.
According to data from the Russian Intellectual Property Office in August 2023, BAT has submitted an application for the registration of the Vuse Pro trademark.
The media reports that Vuse, the first disposable e-cigarette brand launched by a major market participant in Russia, has introduced three products in the Russian market. These include the Vuse Pro, priced at 1,300 rubles, which can be used for 5,000 puffs; the Vuse Go, priced at 800 rubles, which offers 1,500 puffs; and the Vuse Go, priced at 550 rubles, allowing for 600 puffs. All of these products are also available in stores carrying the glo brand.
Earlier, BAT announced its agreement to sell its businesses in Russia and Belarus to a consortium led by a Russian management team. The buyer is a consortium led by the BAT Russia management team. After the completion of the transaction, these two enterprises will belong to them, while the original trademarks will remain unchanged.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
